Kernel develops non-invasive brain measurement technology for neuroscience, health, and human performance applications.
This slot renders the company's funding history: dates, rounds, amounts, valuations and lead investors once populated in data/funding-rounds.json.
Bryan Johnson's Kernel optical brain interface captures high-fidelity neural data showing psilocybin and 5-MeO-DMT dramatically rewire default mode network connectivity, enabling quantified measurement of psychedelic-induced neuroplasticity as a longevity biomarker.